Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice

Current Medical Research and Opinion

Volumn 21, Issue 8, 2005, Pages 1261-1269

  Kemper, Ferry ^a   Gebhardt, Ullricht ^b   Meng, Thomas ^c   Murray, Christopher ^d  

^a Klinik Lohrey   (Germany)

^b Facharzt für Chirurgie ^*  (Germany)

^c Wyeth Pharma GmbH   (Germany)

^d GENZYME CORPORATION   (United States)

Author keywords

Adverse events; Hyaluronan; Hylan G F 20; Knee; Osteoarthritis; Pain

Indexed keywords

ANALGESIC AGENT; ANTIRHEUMATIC AGENT; GLUCOCORTICOID; HYALURONIC ACID; HYLAN G F 20; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ARTHRALGIA; ARTHROPATHY; ARTICLE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEMALE; GENDER; GERMANY; HEAT; HUMAN; INJECTION SITE REACTION; JOINT EFFUSION; JOINT SWELLING; JOINT WARMTH; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; RISK FACTOR; UNDERWEIGHT;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GERMANY; HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; KNEE; KNEE JOINT; MALE; MIDDLE AGED; OBSERVATION; ORTHOPEDICS; OSTEOARTHRITIS, KNEE; PAIN; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 23744456460     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X56501     Document Type: Article

References (17)

1. Dieppe P, Lim K. Osteoarthritis and related disorders. In: Klippel JH, Dieppe P, editors. Rheumatology. Philadelphia: Mosby; 2000
2. World Health Organization. The burden of musculoskeletal conditions at the start of the new millennium. Report of a WHO Scientific Group. WHO Technical Report Series 2003;919:1-218
3. Balazs EA, Watson D, Duff IF, et al. Hyaluronic acid in synovial fluid. I. Molecular parameters of hyaluronic acid in normal and arthritic human fluids. Arthritis Rheum 1967;10:357-76
4. Schurz J, Ribitsch V. Rheology of synovial fluid. Biorheology 1987;24:385-99
5. Adams ME, Atkinson MH, Lussier AJ, et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with nonsteroidal anti- inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage 1995;3:213-25
6. Lussier A, Cividino AA, McFarlane CA, et al. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol 1996;23:1579-85
7. Wobig M, Dickhut A, Maier R, et al. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 1998;20:410-23
8. Scale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr Ther Res 1994;55:220-32
9. Wobig M, Beks P, Dickhut A, et al. Open-label multicenter trial of the safety and efficacy of viscosupplementation with hylan G-F 20 (Synvisc) in primary osteoarthritis of the knee. J Clin Rheumatol 1999;5:S24-31
10. Wobig M, Bach G, Beks P, et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther 1999;21:1549-62
11. Raynauld JP, Torrance G, Band P, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage 2002;10:506-17
12. Synvisc® (hylan G-F 20) Product Information. Genzyme Biosurgery, 2003
13. Waddell DD, Cefalu CA, Bricker DC. An open-label study of a second course of hylan G-F 20 for the treatment of pain associated with knee osteoarthritis. Curr Med Res Opin 2003;19:499-507
14. Leopold SS, Warme WJ, Pettis PD, et al. Increased frequency of acute local reaction to intra-articular hylan GF-20 (Synvisc) in patients receiving more than one course of treatment. J Bone Joint Surg Am 2002;84-A:1619-23
15. Larsen NE, Pollak CT, Reiner K, et al. Hylan gel biomaterial: dermal and immunologic compatibility. J Biomed Mater Res 1993;27:1129-34
16. Sasaki M, Miyazaki T, Nakamura T, et al. Immunogenicity of hylan G-F 20 in guinea pigs and mice. J Rheumatol 2004;31:943-50
17. Lee S, Park D, Chmell SJ. Viscosupplementation with hylan G-F 20 (Synvisc*): pain and mobility observations from 74 consecutive patients. J Knee Surg 2004;17:73-7